Form4insider filings, from the source

SEC Form 4 · accession 0001179110-19-000536

IDERA PHARMACEUTICALS, INC. · IDRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jonathan Michael Yingling
Officer — Chief Scientific Officer
Period of report
Jan 3, 2019
Accepted (ET)
Jan 7, 2019 · 8:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Jan 3, 2019A18,100$0.00A18,100D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2$3.14Jan 3, 2019A45,500A—Jan 3, 2029Common Stock45,50045,500D

Explanation of responses